Alecnib 150 MG (Alectinib)
Product Name : Alecnib
Generic Name : Alectinib
Formulation : Tablet
Available Pack Size : 56’s
Available Strengths : 150 mg
Registrations : Export Only
Product Information
Alecnib (Alectinib) 150mg is a highly selective, second-generation ALK and RET tyrosine kinase inhibitor used for the adjuvant and first-line treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC), as well as for ALK-positive metastatic NSCLC that has progressed on crizotinib. It works by blocking ALK phosphorylation and downstream signalling pathways (including STAT3 and PI3K/AKT), inducing programmed cell death in ALK-driven tumour cells, and is notable for its strong penetration into the central nervous system. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Alecnib (Alectinib) 150mg
| Brand Name | Alecnib (Alectinib) |
| Generic Name | Alectinib (as Alectinib Hydrochloride) INN |
| Drug Class | Highly Selective ALK and RET Tyrosine Kinase Inhibitor |
| Available Strength | 150mg |
| Formulation | Capsule |
| Pack Size | 56 Capsules per Pack |
| Primary Indication | ALK-Positive Non-Small Cell Lung Cancer (Adjuvant, First-Line, and Post-Crizotinib Settings) |
| Regulatory Approvals | USFDA Approved (Adjuvant, First-Line and Post-Crizotinib ALK+ NSCLC). EMA Approved. |
| Originator Brand | Alecensa by Roche/Genentech |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Status | Export Only – Manufactured for International Markets |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry, cool place away from light and moisture. Keep out of the reach of children. |
How Alecnib (Alectinib) Works
Alecnib contains Alectinib, a highly selective and potent inhibitor of the ALK (anaplastic lymphoma kinase) and RET tyrosine kinases. In certain lung cancers, chromosomal rearrangements create an abnormal ALK fusion protein that is constitutively active, continuously driving tumour cell growth and survival. Inhibition of ALK activity blocks downstream signalling pathways, including STAT3 and PI3K/AKT, and induces programmed cell death (apoptosis) in ALK-driven tumour cells.
Alectinib has demonstrated activity against several mutant forms of ALK that confer resistance to crizotinib, an earlier-generation ALK inhibitor. Notably, Alectinib is not a substrate of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP), the efflux transporters that normally limit drug penetration across the blood-brain barrier. This allows Alecnib to distribute into and be retained within the central nervous system, giving it particular value for patients with brain metastases, a common complication of ALK-positive NSCLC.
Alecnib is taken as a twice-daily oral capsule with food, used either as adjuvant therapy after surgical removal of the tumour, as first-line treatment for metastatic disease, or after prior treatment with crizotinib.
Indications for Alecnib (Alectinib)
Alecnib (Alectinib) is indicated for the following conditions:
|
Adjuvant Treatment After Tumour Resection For adult patients following surgical resection of ALK-positive NSCLC (tumours 4cm or larger, or node-positive disease), as detected by an approved test. |
First-Line Metastatic NSCLC For adult patients with ALK-positive metastatic NSCLC, as detected by an approved test, as an initial treatment option. |
|
Post-Crizotinib Metastatic NSCLC For adult patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib, including disease harbouring certain crizotinib-resistance mutations. |
|
Benefits of Alecnib (Alectinib) 150mg
|
Strong CNS Penetration Because Alectinib evades key blood-brain barrier efflux transporters, Alecnib achieves meaningful activity against brain metastases, a frequent and difficult-to-treat feature of ALK-positive NSCLC. |
Active Across Multiple Treatment Stages Approved for adjuvant therapy after surgery, first-line metastatic disease, and after progression on crizotinib, Alecnib supports patients across several stages of ALK-positive NSCLC. |
Active Against Resistance Mutations Alectinib retains activity against several ALK mutations that confer resistance to crizotinib, extending treatment options for patients who have progressed on earlier ALK-inhibitor therapy. |
|
Affordable Alternative to Alecensa Alecnib contains the same active ingredient as Alecensa by Roche/Genentech, at a significantly lower cost, making long-term targeted lung cancer therapy more financially accessible. |
Well-Tolerated Long-Term Safety Profile Alectinib has demonstrated a manageable, well-characterised long-term safety profile across large clinical trials, supporting extended treatment durations where clinically beneficial. |
cGMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Alecnib capsules. |
How to Take Alecnib (Alectinib)
Route: Oral, taken with food. Capsules should be swallowed whole and not opened, crushed, dissolved, or chewed.
Standard dose: 600mg (four 150mg capsules) taken twice daily with food, for a total daily dose of 1200mg, continued until disease progression or unacceptable toxicity, exactly as directed by the prescribing oncologist.
Severe hepatic impairment (Child-Pugh C): The recommended starting dose is 450mg (three 150mg capsules) twice daily with food, for a total daily dose of 900mg.
Missed dose: A missed dose can be made up unless the next scheduled dose is due within 6 hours; do not take two doses at the same time. If vomiting occurs after a dose, take the next dose at its normal scheduled time rather than an extra dose.
Dose reduction for toxicity: The dose is typically reduced in steps of 150mg per dose to manage adverse reactions, as directed by the prescribing physician; treatment is generally discontinued if a dose of 300mg twice daily cannot be tolerated.
Renal impairment: No dose adjustment is generally required in mild to moderate renal impairment. Alecnib has not been extensively studied in severe renal impairment.
Sun exposure: Alectinib can increase sensitivity to sunlight. Avoid prolonged sun exposure, wear protective clothing, and use a broad-spectrum sunscreen (SPF 50 or higher) during treatment and for at least 7 days after the final dose.
Paediatric use: The safety and efficacy of Alecnib in children and adolescents have not been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Alecnib treatment. Your oncologist will check liver function tests every 2 weeks during the first 3 months of treatment, then monthly and as clinically indicated, with more frequent testing in patients who develop elevated liver enzymes. Monitoring also includes heart rate for bradycardia, creatine phosphokinase (CPK) levels for muscle-related toxicity, complete blood counts for haemolytic anaemia, and prompt evaluation of any new or worsening respiratory symptoms suggestive of pneumonitis. Report any yellowing of the skin or eyes, unusual fatigue, muscle pain or weakness, dizziness, fainting, breathlessness, or skin reactions to your doctor immediately.
Drug Interactions and Important Information
Use with caution alongside other medicines known to slow heart rate, such as beta-blockers or certain calcium channel blockers, due to the risk of bradycardia. Alectinib’s major metabolite is a substrate of P-glycoprotein (P-gp), so caution is advised with strong P-gp inhibitors or inducers, though Alectinib itself is not significantly affected by cytochrome P450-mediated interactions in the way many other targeted therapies are.
Inform your physician of any history of liver disease, slow heart rate, or muscle disorders before starting treatment. Women of childbearing potential should use effective contraception during treatment and for at least 1 week after the final dose; men should use effective contraception for at least 3 months after their final dose. Breastfeeding should be avoided during treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Alecnib.
Side Effects and Precautions
|
Common Side Effects Constipation Fatigue and oedema (swelling) Myalgia (muscle pain) Nausea and vomiting Elevated liver enzymes and bilirubin Weight gain Anaemia and low blood counts Photosensitivity (increased sun sensitivity) |
Serious Warnings and Precautions Hepatotoxicity, requiring regular liver function monitoring, particularly in the first three months of treatment. Interstitial lung disease/pneumonitis, including cases that can be severe. Bradycardia (slow heart rate), particularly when combined with other heart-rate-lowering medicines. Severe myalgia with elevated creatine phosphokinase (CPK). Haemolytic anaemia and gastrointestinal perforation, both rare. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Alecnib (Alectinib)?
Alecnib is suitable for adult patients with ALK-positive Non-Small Cell Lung Cancer, confirmed by an approved diagnostic test, whether being treated after surgical tumour resection, as first-line therapy for metastatic disease, or following progression on or intolerance to crizotinib. It is prescribed by medical and thoracic oncologists experienced in biomarker-guided cancer therapy. A thorough medical assessment including ALK testing, baseline liver function, heart rate, and CPK levels is required before initiating treatment.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Alecnib under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Alecnib is registered with the Directorate General of Drug Administration (DGDA) of Bangladesh, and offers a bioequivalent alternative to Alecensa by Roche/Genentech at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Alecnib (Alectinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Alecnib (Alectinib) from Mediaid Pharmacy?
Alecnib represents an important, brain-penetrant option in the treatment of ALK-positive lung cancer. As the generic equivalent of Alecensa by Roche/Genentech, it delivers the same active ingredient, Alectinib, with the same proven ALK-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Alecnib gives patients worldwide access to precision lung cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Alectinib option with worldwide delivery, Alecnib from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Alecnib (Alectinib)
What is Alecnib (Alectinib) used for?
Alecnib (Alectinib) is used to treat adult patients with ALK-positive Non-Small Cell Lung Cancer, either as adjuvant therapy after surgical tumour resection, as first-line treatment for metastatic disease, or after progression on or intolerance to crizotinib. It works by blocking the abnormal ALK signalling that drives tumour growth, with particularly good activity in the brain.
How should I take Alecnib (Alectinib)?
Alecnib capsules are taken orally, twice daily, always with food, since food is needed for proper absorption. The standard dose is 600mg (four 150mg capsules) twice daily. A reduced starting dose of 450mg twice daily is used in patients with severe hepatic impairment. Always follow your oncologist’s exact instructions.
What strength is Alecnib (Alectinib) available in?
Alecnib is available in a 150mg capsule, supplied in a pack of 56 capsules. Because Alecnib is available in the 150mg strength, higher doses are achieved by taking the appropriate number of capsules per dose, exactly as prescribed by your physician.
Is Alecnib the same as Alecensa (Alectinib by Roche)?
Yes. Alecnib is the generic equivalent of Alecensa. Both contain the same active ingredient, Alectinib, and work through the same ALK-inhibition mechanism. Alecnib is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offers the same clinical mechanism as Alecensa at a significantly lower cost.
What are the side effects of Alecnib (Alectinib)?
Common side effects include constipation, fatigue, muscle pain, nausea, swelling, and weight gain. Serious but less common risks include liver injury, lung inflammation, slow heart rate, severe muscle pain with elevated CPK, and increased sun sensitivity. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.
Can Alecnib be used with other medications?
Use caution combining Alecnib with other medicines that slow heart rate, such as beta-blockers. Alectinib’s major metabolite is affected by P-glycoprotein interactions, so inform your physician of all medications you are taking. Sun exposure should be minimised, with protective clothing and high-SPF sunscreen used during and after treatment.
Is Alecnib (Alectinib) safe during pregnancy or breastfeeding?
No. Alecnib is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 1 week after the final dose, and men should use contraception for at least 3 months after their final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Alecnib (Alectinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Alecnib (Alectinib) 150mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Alecnib (Alectinib) 150mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
